Neuren Pharmaceuticals Upgrades 2026 Guidance to US$91–93M After 39% Q3 DAYBUE Sales Rise and US$35M Germany Milestone

Anjali Anand

05 November 2026 03:14 PM AEDT

Neuren Pharmaceuticals Upgrades 2026 Guidance to US$91–93M After 39% Q3 DAYBUE Sales Rise and US$35M Germany Milestone

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Neuren Pharmaceuticals (ASX:NEU) has upgraded its full year 2026 total income guidance from trofinetide to US$91–93 million, following Q3 2026 DAYBUE net sales of US$140 million — up 39% from Q3 2025 — and the receipt of a US$35 million milestone payment triggered by the first commercial sale of DAYBUE in Germany in October 2026.

Key Points

Neuren's full year 2026 total income guidance from trofinetide upgraded to US$91–93 million, from US$53–56 million previously
Q3 2026 DAYBUE net sales of US$140 million, up 39% from Q3 2025 and up 12% from Q2 2026
Neuren earned Q3 2026 royalty income of US$16.4 million, up 51% from Q3 2025
US$35 million milestone payment earned on DAYBUE launch in Germany in October 2026
Japan Phase 3 study results described as consistent with the LAVENDER Phase 3 study and supportive of a planned regulatory filing in 2027, with potential launch in 2028 subject to regulatory approval

DAYBUE Sales Performance and Acadia Guidance Upgrade

Partner Acadia Pharmaceuticals reported Q3 2026 DAYBUE net sales of US$140 million, up 39% on Q3 2025 and up 12% on Q2 2026. Acadia increased its full year 2026 global net sales guidance for DAYBUE to US$505–520 million, from a previous range of US$480–510 million. Sales growth in the quarter was driven by strong uptake of DAYBUE STIX by existing patients, as well as new patient starts and patient restarts. More than 50% of US DAYBUE users are already on DAYBUE STIX, up from 40% at the end of Q2 2026. During Q3, a new US patent was allowed covering weight-banded dosing of trofinetide, extending US patent protections for DAYBUE and DAYBUE STIX through March 2041.

Germany Launch and European Licence Entitlements

DAYBUE was launched in Germany in October 2026, with patients already receiving treatment. The first commercial sale triggered a US$35 million milestone payment to Neuren under its licence agreement. Under the European licence — covering all European Union member states as of 13 July 2023, plus the United Kingdom, Iceland, Norway, Switzerland and Liechtenstein — Neuren is entitled to tiered royalty rates ranging from 17% on annual net sales up to US$150 million, to 23% on annual net sales above US$300 million. Additional sales milestone payments of between US$15 million and US$75 million are payable once each at defined net sales thresholds.

Neuren Royalty Income and Japan Regulatory Plans

Neuren earned royalty income of US$16.4 million in Q3 2026, up 51% from Q3 2025. Full year 2026 anticipated royalties increased to US$56–58 million, from the previous range of US$53–56 million. Including the US$35 million European milestone payment, Neuren's total income from trofinetide for 2026 is expected to be US$91–93 million. Acadia has completed its Phase 3 study of trofinetide in Rett syndrome in Japan, with results described as consistent with the LAVENDER Phase 3 study. Acadia continues to pursue a distribution partner in preparation for a regulatory filing in 2027 and a potential launch in 2028, subject to regulatory approval.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.